WuXi Biologics wins ABL Bio contract for bispecific antibodies

By Flora Southey contact

- Last updated on GMT

(Image: Getty/Ruskpp)
(Image: Getty/Ruskpp)

Related tags: CDMO, Wuxi biologics, South korea, China

South Korean biotech ABL Bio has selected WuXi Biologics to develop and manufacture up to eight bispecific antibodies for the clinic.

ABL Bio Corporation’s bispecific antibodies, which bind two different epitopes either on the same or different targets, are being developed for immune-oncology and neurodegenerative diseases.

WuXi Biologics and ABL Bio’s agreement will see the Chinese contract development and manufacturing organisation (CDMO) prepare up to eight bispecific antibodies for clinical trials.

Candidates will be selected from both ABL Bio’s pipeline and collaboration programmes​ between ABL Bio and I-Mab Biopharma.

“The partnership with WuXi Biologics is an important strategy for growing our internal and external programmes of next-generation…biologics, such as [the] bispecific antibody,” ​said ABL Bio CEO Sang Hoon Lee in a statement.

For WuXi Biologics, the exclusive partnership marks its first in South Korea. The CDMO is expanding internationally, with an estimated capacity of 220,000 litres planned across China, Ireland​, Singapore​, and the US​ by 2021.

Earlier this month, the firm broke ground​ on its eight drug substance manufacturing facility – located in China’s Hebei province – and announced plans​ to build a discovery, development and manufacturing site in the Fengxian district of Shanghai.

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars